Immunogenicity, reactogenicity, and safety to assess booster vaccinations with BNT162b2 or double-dose mRNA-1273 in adults =75 years (EU-COVAT-1-AGED)-final report


Por: Stemler, J, Yeghiazaryan, L, Stephan, C, Mohn, KG, Cox, RJ, Carcas-Sansuan, AJ, Rodriguez, ER, Moltó, J, Mitxeltorena, IV, Pink, I, Welte, T, Zablockiene, B, Akova, M, Bethe, U, Grimm, S, Salmanton-Garcia, J, Jakobs, J, Tischmann, L, Zarrouk, M, Cüppers, A, Biehl, LM, Grothe, J, Mellinghoff, SC, Nacov, JA, Neuhann, JM, Sprute, R, Frias-Iniesta, J, Negi, R, Gaillard, C, Saini, G, León, AG, Mallon, PWG, Lammens, C, Hotterbeekx, A, Loens, K, Malhotra-Kumar, S, Goossens, H, Kumar-Singh, S, König, F, Posch, M, Koehler, P and Cornely, OA

Publicada: 1 abr 2026
Resumen:
Background: To determine long-term immunogenicity and reactogenicity of different SARS-CoV-2 messenger RNA (mRNA) vaccines in a population >= 75 years of age in a randomized trial. Methods: Participants were randomized to receive either BNT162b2 30 & micro;g or a double booster dose of mRNA-1273, i.e., 100 & micro;g, as the third and fourth vaccinations (first and second booster). The primary endpoint was the rate of a two-fold geometric mean titer (GMT) antibody increase 14 days after vaccination targeting the receptor binding domain (RBD) region of wild-type SARS-CoV-2. Secondary endpoints included neutralizing capacity against wild-type and 25 variants at 14 days (D14) and 12 months (M12). Safety was assessed by monitoring adverse events (AEs) for 7 days after vaccination. Findings: Between November 2021 and September 2022, 322 participants received a SARS-CoV-2 vaccine as a first (Part A) or second booster (Part B). Primary endpoint results have been published previously. In Part A, it was reached by 100% of participants in both vaccine arms, with a higher GMT increase in the mRNA-1273 arm (ratio, 1.64). At M12, the GMT of anti-RBD immunoglobulin G (IgG) was slightly higher than at D14 (9319.7 vs 8568.4 IU/mL) in the BNT162b2 arm, while in the mRNA-1273 arm, the GMT was equal (14,163.8 vs 14,266.7 IU/mL at D14). In Part B, the primary endpoint was reached by 78.5% of participants in the BNT162b2 and 87.2% in the mRNA-1273 arm (P = 0.056), respectively, with a higher GMT increase of anti-RBD IgG for mRNA-1273 (ratio, 1.38). At M12, GMT of anti-RBD IgG was markedly lower than at D14 (9962 vs 15,248.2 IU/mL) in the BNT162b2 arm as well as in the mRNA-1273 arm (12,024.3 vs 21,325.6 IU/mL). Higher neutralizing capacity in individuals who received a booster with mRNA-1273 was detected against wild-type and 15 of 25 tested variants. Fewer participants in the mRNA-1273 arm had vaccine-related AEs (29.6% vs 38.5%), but severity was more frequently grade 2 (n = 38, 28.1% vs n = 22, 16.3%). Interpretation: Long-term serological immunogenicity and virus neutralization capacity in participants >= 75 years of age were numerically better with an mRNA-1273 100 & micro;g booster, with a comparable safety profile. (c) 2026 The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/)

Filiaciones:
Stemler, J:
 Univ Cologne, Inst Translat Res, Fac Med, Cologne Excellence Cluster Cellular Stress Respons, Cologne, Germany

 Univ Cologne, Univ Hosp Cologne, Cologne, Germany

 Univ Cologne, Fac Med, Ctr Integrated Oncol Aachen Bonn Cologne Duesseldo, Dept Internal Med 1, Cologne, Germany

 Univ Cologne, Fac Med, Excellence Ctr Med Mycol ECMM, Cologne, Germany

 Univ Hosp Cologne, Cologne, Germany

 German Ctr Infect Res DZIF, Partner Site Bonn Cologne, Cologne, Germany

Yeghiazaryan, L:
 Med Univ Vienna, Inst Med Stat, Ctr Med Data Sci, Vienna, Austria

Stephan, C:
 Univ Hosp Frankfurt, Dept Internal Med, Infect Dis, Frankfurt, Germany

Mohn, KG:
 Haukeland Hosp, Dept Microbiol, Helse Bergen HF, Bergen, Norway

 Univ Bergen, Influenza Ctr, Dept Clin Sci, Bergen, Norway

Cox, RJ:
 Haukeland Hosp, Dept Microbiol, Helse Bergen HF, Bergen, Norway

 Univ Bergen, Influenza Ctr, Dept Clin Sci, Bergen, Norway

Carcas-Sansuan, AJ:
 Univ Autonoma Madrid, Inst Hlth Res IdiPAZ, Fac Med, Clin Pharmacol Serv,Hosp Univ La Paz, Madrid, Spain

Rodriguez, ER:
 Dist Sanitario Cordoba Guadalquivir, Primary Care Unit, Isla Lanzarote s-n, Cordoba, Spain

 Univ Cordoba, Reina Sofia Univ Hosp, Maimonides Biomed Res Inst Cordoba IMIBIC, Cordoba, Spain

:
 Hosp Univ Germans, Dept Infect Dis, Fundacio Lluita Infecc, Barcelona, Spain

 Inst Salud Carlos III, CIBER Enfermedades Infecciosas CIBERInfec, Madrid, Spain

Mitxeltorena, IV:
 Inst Salud Carlos III, CIBER Enfermedades Infecciosas CIBERInfec, Madrid, Spain

 Gipuzkoa Integrated Hlth Org, Asociac Inst BIODONOSTIA, Primary Care Res Unit, San Sebastian, Gipuzkoa, Spain

Pink, I:
 Hannover Med Sch, Dept Resp Med & Infect Dis, Hannover, Germany

Welte, T:
 Hannover Med Sch, Dept Resp Med & Infect Dis, Hannover, Germany

Zablockiene, B:
 Vilnius Univ Hosp, Ctr Infect Dis, Santaros Klin, Vilnius, Lithuania

 Vilnius Univ, Fac Med, Inst Clin Med, Clin Infect Dis Dermatovenerol, Vilnius, Lithuania

Akova, M:
 Hacettepe Univ, Sch Med, Dept Infect Dis, Ankara, Turkiye

Bethe, U:
 Univ Cologne, Inst Translat Res, Fac Med, Cologne Excellence Cluster Cellular Stress Respons, Cologne, Germany

 Univ Cologne, Univ Hosp Cologne, Cologne, Germany

 Univ Cologne, Fac Med, Ctr Integrated Oncol Aachen Bonn Cologne Duesseldo, Dept Internal Med 1, Cologne, Germany

 Univ Cologne, Fac Med, Excellence Ctr Med Mycol ECMM, Cologne, Germany

 Univ Hosp Cologne, Cologne, Germany

 German Ctr Infect Res DZIF, Partner Site Bonn Cologne, Cologne, Germany

Grimm, S:
 Univ Cologne, Inst Translat Res, Fac Med, Cologne Excellence Cluster Cellular Stress Respons, Cologne, Germany

 Univ Cologne, Univ Hosp Cologne, Cologne, Germany

 Univ Cologne, Fac Med, Ctr Integrated Oncol Aachen Bonn Cologne Duesseldo, Dept Internal Med 1, Cologne, Germany

 Univ Cologne, Fac Med, Excellence Ctr Med Mycol ECMM, Cologne, Germany

 Univ Hosp Cologne, Cologne, Germany

 German Ctr Infect Res DZIF, Partner Site Bonn Cologne, Cologne, Germany

Salmanton-Garcia, J:
 Univ Cologne, Inst Translat Res, Fac Med, Cologne Excellence Cluster Cellular Stress Respons, Cologne, Germany

 Univ Cologne, Univ Hosp Cologne, Cologne, Germany

 Univ Cologne, Fac Med, Ctr Integrated Oncol Aachen Bonn Cologne Duesseldo, Dept Internal Med 1, Cologne, Germany

 Univ Cologne, Fac Med, Excellence Ctr Med Mycol ECMM, Cologne, Germany

 Univ Hosp Cologne, Cologne, Germany

 German Ctr Infect Res DZIF, Partner Site Bonn Cologne, Cologne, Germany

Jakobs, J:
 Univ Cologne, Inst Translat Res, Fac Med, Cologne Excellence Cluster Cellular Stress Respons, Cologne, Germany

 Univ Cologne, Univ Hosp Cologne, Cologne, Germany

 Univ Cologne, Fac Med, Ctr Integrated Oncol Aachen Bonn Cologne Duesseldo, Dept Internal Med 1, Cologne, Germany

 Univ Cologne, Fac Med, Excellence Ctr Med Mycol ECMM, Cologne, Germany

 Univ Hosp Cologne, Cologne, Germany

 German Ctr Infect Res DZIF, Partner Site Bonn Cologne, Cologne, Germany

Tischmann, L:
 Univ Cologne, Inst Translat Res, Fac Med, Cologne Excellence Cluster Cellular Stress Respons, Cologne, Germany

 Univ Cologne, Univ Hosp Cologne, Cologne, Germany

 Univ Cologne, Fac Med, Ctr Integrated Oncol Aachen Bonn Cologne Duesseldo, Dept Internal Med 1, Cologne, Germany

 Univ Cologne, Fac Med, Excellence Ctr Med Mycol ECMM, Cologne, Germany

 Univ Hosp Cologne, Cologne, Germany

 German Ctr Infect Res DZIF, Partner Site Bonn Cologne, Cologne, Germany

Zarrouk, M:
 Univ Cologne, Inst Translat Res, Fac Med, Cologne Excellence Cluster Cellular Stress Respons, Cologne, Germany

 Univ Cologne, Univ Hosp Cologne, Cologne, Germany

Cüppers, A:
 Univ Cologne, Fac Med, Clin Trials Ctr Cologne CTCC Cologne, Cologne, Germany

Biehl, LM:
 Univ Cologne, Fac Med, Ctr Integrated Oncol Aachen Bonn Cologne Duesseldo, Dept Internal Med 1, Cologne, Germany

 Univ Cologne, Fac Med, Excellence Ctr Med Mycol ECMM, Cologne, Germany

 Univ Hosp Cologne, Cologne, Germany

 German Ctr Infect Res DZIF, Partner Site Bonn Cologne, Cologne, Germany

 Fraunhofer Inst Translat Med & Pharmacol ITMP, Frankfurt, Germany

 Fraunhofer Cluster Excellence Immune Mediated Dis, Frankfurt, Germany

Grothe, J:
 Univ Cologne, Inst Translat Res, Fac Med, Cologne Excellence Cluster Cellular Stress Respons, Cologne, Germany

 Univ Cologne, Univ Hosp Cologne, Cologne, Germany

 Univ Cologne, Fac Med, Ctr Integrated Oncol Aachen Bonn Cologne Duesseldo, Dept Internal Med 1, Cologne, Germany

 Univ Cologne, Fac Med, Excellence Ctr Med Mycol ECMM, Cologne, Germany

 Univ Hosp Cologne, Cologne, Germany

 German Ctr Infect Res DZIF, Partner Site Bonn Cologne, Cologne, Germany

Mellinghoff, SC:
 Univ Cologne, Inst Translat Res, Fac Med, Cologne Excellence Cluster Cellular Stress Respons, Cologne, Germany

 Univ Cologne, Univ Hosp Cologne, Cologne, Germany

 Univ Cologne, Fac Med, Ctr Integrated Oncol Aachen Bonn Cologne Duesseldo, Dept Internal Med 1, Cologne, Germany

 Univ Cologne, Fac Med, Excellence Ctr Med Mycol ECMM, Cologne, Germany

 Univ Hosp Cologne, Cologne, Germany

 German Ctr Infect Res DZIF, Partner Site Bonn Cologne, Cologne, Germany

Nacov, JA:
 Univ Cologne, Inst Translat Res, Fac Med, Cologne Excellence Cluster Cellular Stress Respons, Cologne, Germany

 Univ Cologne, Univ Hosp Cologne, Cologne, Germany

 Univ Cologne, Fac Med, Ctr Integrated Oncol Aachen Bonn Cologne Duesseldo, Dept Internal Med 1, Cologne, Germany

 Univ Cologne, Fac Med, Excellence Ctr Med Mycol ECMM, Cologne, Germany

 Univ Hosp Cologne, Cologne, Germany

 German Ctr Infect Res DZIF, Partner Site Bonn Cologne, Cologne, Germany

Neuhann, JM:
 Univ Cologne, Inst Translat Res, Fac Med, Cologne Excellence Cluster Cellular Stress Respons, Cologne, Germany

 Univ Cologne, Univ Hosp Cologne, Cologne, Germany

 Univ Cologne, Fac Med, Ctr Integrated Oncol Aachen Bonn Cologne Duesseldo, Dept Internal Med 1, Cologne, Germany

 Univ Cologne, Fac Med, Excellence Ctr Med Mycol ECMM, Cologne, Germany

 Univ Hosp Cologne, Cologne, Germany

 German Ctr Infect Res DZIF, Partner Site Bonn Cologne, Cologne, Germany

Sprute, R:
 Univ Cologne, Inst Translat Res, Fac Med, Cologne Excellence Cluster Cellular Stress Respons, Cologne, Germany

 Univ Cologne, Univ Hosp Cologne, Cologne, Germany

 Univ Cologne, Fac Med, Ctr Integrated Oncol Aachen Bonn Cologne Duesseldo, Dept Internal Med 1, Cologne, Germany

 Univ Cologne, Fac Med, Excellence Ctr Med Mycol ECMM, Cologne, Germany

 Univ Hosp Cologne, Cologne, Germany

 German Ctr Infect Res DZIF, Partner Site Bonn Cologne, Cologne, Germany

Frias-Iniesta, J:
 Univ Cologne, Inst Translat Res, Fac Med, Cologne Excellence Cluster Cellular Stress Respons, Cologne, Germany

 Univ Cologne, Univ Hosp Cologne, Cologne, Germany

Negi, R:
 Univ Coll Dublin, Ctr Expt Pathogen Host Res CEPHR, Sch Med, Belfield, Ireland

Gaillard, C:
 Univ Coll Dublin, Ctr Expt Pathogen Host Res CEPHR, Sch Med, Belfield, Ireland

Saini, G:
 Univ Coll Dublin, Ctr Expt Pathogen Host Res CEPHR, Sch Med, Belfield, Ireland

León, AG:
 Univ Coll Dublin, Ctr Expt Pathogen Host Res CEPHR, Sch Med, Belfield, Ireland

Mallon, PWG:
 Univ Coll Dublin, Ctr Expt Pathogen Host Res CEPHR, Sch Med, Belfield, Ireland

Lammens, C:
 Univ Antwerp, Vaccine & Infect Dis Inst, Lab Med Microbiol, Antwerp, Belgium

 Univ Antwerp, Biobank Antwerp, Antwerp, Belgium

Hotterbeekx, A:
 Univ Antwerp, Mol Pathol Grp, Fac Med, Lab Cell Biol & Histol CBH, Antwerp, Belgium

 Univ Antwerp, Vaccine & Infect Dis Inst CBH, Fac Med, Antwerp, Belgium

Loens, K:
 Univ Antwerp, Vaccine & Infect Dis Inst, Lab Med Microbiol, Antwerp, Belgium

 Univ Antwerp, Biobank Antwerp, Antwerp, Belgium

Malhotra-Kumar, S:
 Univ Antwerp, Vaccine & Infect Dis Inst, Lab Med Microbiol, Antwerp, Belgium

 Univ Antwerp, Biobank Antwerp, Antwerp, Belgium

Goossens, H:
 Univ Antwerp, Vaccine & Infect Dis Inst, Lab Med Microbiol, Antwerp, Belgium

 Univ Antwerp, Biobank Antwerp, Antwerp, Belgium

Kumar-Singh, S:
 Univ Antwerp, Mol Pathol Grp, Fac Med, Lab Cell Biol & Histol CBH, Antwerp, Belgium

 Univ Antwerp, Vaccine & Infect Dis Inst CBH, Fac Med, Antwerp, Belgium

König, F:
 Med Univ Vienna, Inst Med Stat, Ctr Med Data Sci, Vienna, Austria

Posch, M:
 Med Univ Vienna, Inst Med Stat, Ctr Med Data Sci, Vienna, Austria

Koehler, P:
 Univ Cologne, Inst Translat Res, Fac Med, Cologne Excellence Cluster Cellular Stress Respons, Cologne, Germany

 Univ Cologne, Univ Hosp Cologne, Cologne, Germany

 Univ Cologne, Fac Med, Ctr Integrated Oncol Aachen Bonn Cologne Duesseldo, Dept Internal Med 1, Cologne, Germany

 Univ Cologne, Fac Med, Excellence Ctr Med Mycol ECMM, Cologne, Germany

 Univ Hosp Cologne, Cologne, Germany

 Univ Cologne, Fac Med, Cologne, Germany

 Univ Hosp Cologne, Dept Internal Med 1, Div Clin Immunol, Cologne, Germany

Cornely, OA:
 Univ Cologne, Inst Translat Res, Fac Med, Cologne Excellence Cluster Cellular Stress Respons, Cologne, Germany

 Univ Cologne, Univ Hosp Cologne, Cologne, Germany

 Univ Cologne, Fac Med, Ctr Integrated Oncol Aachen Bonn Cologne Duesseldo, Dept Internal Med 1, Cologne, Germany

 Univ Cologne, Fac Med, Excellence Ctr Med Mycol ECMM, Cologne, Germany

 Univ Hosp Cologne, Cologne, Germany

 German Ctr Infect Res DZIF, Partner Site Bonn Cologne, Cologne, Germany

 Univ Cologne, Fac Med, Clin Trials Ctr Cologne CTCC Cologne, Cologne, Germany
ISSN: 12019712





International Journal of Infectious Diseases
Editorial
Elsevier BV, THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND, Países Bajos
Tipo de documento: Article
Volumen: 165 Número:
Páginas:
WOS Id: 001712783500001
ID de PubMed: 41655623
imagen gold

MÉTRICAS